Breast Cancer Liquid Biopsy Market Size, Share

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Breast Cancer Liquid Biopsy Market Size Analysis

Global Breast Cancer Liquid Biopsy Market Introduction
By Product and Service
1. Introduction
  1. Product and Service By Value
2. Reagent Kits
  1. By Value
3. Instruments
  1. By Value
4. Services
  1. By Value
By Circulating Biomarker
1. Introduction
  1. Circulating Biomarker By Value
2. Circulating Tumor Cells
  1. By Value
3. Extracellular Vesicles
  1. By Value
4. Circulating Tumor DNA
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Diagnostics
  1. By Value
3. Prognostics
  1. By Value
4. Risk assessment
  1. By Value

North America Market Analysis

Introduction
By Product and Service
1. Introduction
  1. Product and Service By Value
2. Reagent Kits
  1. By Value
3. Instruments
  1. By Value
4. Services
  1. By Value
By Circulating Biomarker
1. Introduction
  1. Circulating Biomarker By Value
2. Circulating Tumor Cells
  1. By Value
3. Extracellular Vesicles
  1. By Value
4. Circulating Tumor DNA
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Diagnostics
  1. By Value
3. Prognostics
  1. By Value
4. Risk assessment
  1. By Value
U.S.
1. By Product and Service
  1. Introduction
    1. Product and Service By Value
  2. Reagent Kits
    1. By Value
  3. Instruments
    1. By Value
  4. Services
    1. By Value
2. By Circulating Biomarker
  1. Introduction
    1. Circulating Biomarker By Value
  2. Circulating Tumor Cells
    1. By Value
  3. Extracellular Vesicles
    1. By Value
  4. Circulating Tumor DNA
    1. By Value
3. By Applications
  1. Introduction
    1. Applications By Value
  2. Diagnostics
    1. By Value
  3. Prognostics
    1. By Value
  4. Risk assessment
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product and Service
1. Introduction
  1. Product and Service By Value
2. Reagent Kits
  1. By Value
3. Instruments
  1. By Value
4. Services
  1. By Value
By Circulating Biomarker
1. Introduction
  1. Circulating Biomarker By Value
2. Circulating Tumor Cells
  1. By Value
3. Extracellular Vesicles
  1. By Value
4. Circulating Tumor DNA
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Diagnostics
  1. By Value
3. Prognostics
  1. By Value
4. Risk assessment
  1. By Value
U.K.
1. By Product and Service
  1. Introduction
    1. Product and Service By Value
  2. Reagent Kits
    1. By Value
  3. Instruments
    1. By Value
  4. Services
    1. By Value
2. By Circulating Biomarker
  1. Introduction
    1. Circulating Biomarker By Value
  2. Circulating Tumor Cells
    1. By Value
  3. Extracellular Vesicles
    1. By Value
  4. Circulating Tumor DNA
    1. By Value
3. By Applications
  1. Introduction
    1. Applications By Value
  2. Diagnostics
    1. By Value
  3. Prognostics
    1. By Value
  4. Risk assessment
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product and Service
1. Introduction
  1. Product and Service By Value
2. Reagent Kits
  1. By Value
3. Instruments
  1. By Value
4. Services
  1. By Value
By Circulating Biomarker
1. Introduction
  1. Circulating Biomarker By Value
2. Circulating Tumor Cells
  1. By Value
3. Extracellular Vesicles
  1. By Value
4. Circulating Tumor DNA
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Diagnostics
  1. By Value
3. Prognostics
  1. By Value
4. Risk assessment
  1. By Value
China
1. By Product and Service
  1. Introduction
    1. Product and Service By Value
  2. Reagent Kits
    1. By Value
  3. Instruments
    1. By Value
  4. Services
    1. By Value
2. By Circulating Biomarker
  1. Introduction
    1. Circulating Biomarker By Value
  2. Circulating Tumor Cells
    1. By Value
  3. Extracellular Vesicles
    1. By Value
  4. Circulating Tumor DNA
    1. By Value
3. By Applications
  1. Introduction
    1. Applications By Value
  2. Diagnostics
    1. By Value
  3. Prognostics
    1. By Value
  4. Risk assessment
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product and Service
1. Introduction
  1. Product and Service By Value
2. Reagent Kits
  1. By Value
3. Instruments
  1. By Value
4. Services
  1. By Value
By Circulating Biomarker
1. Introduction
  1. Circulating Biomarker By Value
2. Circulating Tumor Cells
  1. By Value
3. Extracellular Vesicles
  1. By Value
4. Circulating Tumor DNA
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Diagnostics
  1. By Value
3. Prognostics
  1. By Value
4. Risk assessment
  1. By Value
UAE
1. By Product and Service
  1. Introduction
    1. Product and Service By Value
  2. Reagent Kits
    1. By Value
  3. Instruments
    1. By Value
  4. Services
    1. By Value
2. By Circulating Biomarker
  1. Introduction
    1. Circulating Biomarker By Value
  2. Circulating Tumor Cells
    1. By Value
  3. Extracellular Vesicles
    1. By Value
  4. Circulating Tumor DNA
    1. By Value
3. By Applications
  1. Introduction
    1. Applications By Value
  2. Diagnostics
    1. By Value
  3. Prognostics
    1. By Value
  4. Risk assessment
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product and Service
1. Introduction
  1. Product and Service By Value
2. Reagent Kits
  1. By Value
3. Instruments
  1. By Value
4. Services
  1. By Value
By Circulating Biomarker
1. Introduction
  1. Circulating Biomarker By Value
2. Circulating Tumor Cells
  1. By Value
3. Extracellular Vesicles
  1. By Value
4. Circulating Tumor DNA
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Diagnostics
  1. By Value
3. Prognostics
  1. By Value
4. Risk assessment
  1. By Value
Brazil
1. By Product and Service
  1. Introduction
    1. Product and Service By Value
  2. Reagent Kits
    1. By Value
  3. Instruments
    1. By Value
  4. Services
    1. By Value
2. By Circulating Biomarker
  1. Introduction
    1. Circulating Biomarker By Value
  2. Circulating Tumor Cells
    1. By Value
  3. Extracellular Vesicles
    1. By Value
  4. Circulating Tumor DNA
    1. By Value
3. By Applications
  1. Introduction
    1. Applications By Value
  2. Diagnostics
    1. By Value
  3. Prognostics
    1. By Value
  4. Risk assessment
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Breast Cancer Liquid Biopsy Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Biocept Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
F. Hoffmann-La Roche Ltd. (Foundation Medicine Inc.)
Fluxion Biosciences Inc.
Menarini Group (Menarini Silicon Biosystems Inc.)
Myriad Genetics Inc.
NeoGenomics Laboratories Inc.
Qiagen N.V.
Sysmex Corporation
Thermo Fisher Scientific Inc.
Guardant Health Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment